Q2 2016 13F Holders as of 30 Jun 2016
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
47
-
Total 13F shares, excl. options
-
17.5M
-
Shares change
-
-161K
-
Total reported value, excl. options
-
$61.1M
-
Value change
-
-$710K
-
Put/Call ratio
-
2.34
-
Number of buys
-
18
-
Number of sells
-
-21
-
Price
-
$3.48
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q2 2016
58 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q2 2016.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 47 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.5M shares
of 193M outstanding shares and own 9.07% of the company stock.
Largest 10 shareholders include PRIMECAP MANAGEMENT CO/CA/ (3.85M shares), Falcon Edge Capital LP (2.62M shares), HealthCor Management, L.P. (2.26M shares), D. E. Shaw & Co., Inc. (1.74M shares), SABBY MANAGEMENT, LLC (1.18M shares), BANK OF MONTREAL /CAN/ (811K shares), AXA (792K shares), GOLDMAN SACHS GROUP INC (681K shares), MILLENNIUM MANAGEMENT LLC (586K shares), and SUFFOLK CAPITAL MANAGEMENT LLC (442K shares).
This table shows the top 47 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.